Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Orchid Pharma Ltd

About the Company - Orchid Pharma Ltd

Orchid Pharma Ltd. is a Public Limited Listed company incorporated on 01/07/1992 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24222TN1992PLC022994 and registration number is 022994. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 556.97 Cr. and Equity Capital is Rs. 40.82 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals'Orchid Towers', 313, Valluvar Kottam High Road, Chennai (Madras) Tamil Nadu 600034corporate@orchidpharma.com
http://www.orchidpharma.com
Management
NamePosition Held
Mr. Ram Gopal AgarwalChairman & Non-Exe.Director
Mr. Manish DhanukaManaging Director
Mr. Mridul DhanukaWhole Time Director
Mrs. Tanu SinglaIndependent Director
Dr. Dharam VirIndependent Director
Mr. Manoj Kumar GoyalIndependent Director
Mr. Mudit TandonIndependent Director

Basic Stock Data of Orchid Pharma Ltd

Last Updated: July 24, 2024, 10:49 pm

Market Cap 6,954 Cr.
Current Price 1,370
High / Low1,425/432
Stock P/E75.4
Book Value 231
Dividend Yield0.00 %
ROCE9.32 %
ROE9.92 %
Face Value 10.0
PEG Ratio0.61

Data Source: screener.in

Competitors of Orchid Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Murae Organisor Ltd 36.3 Cr. 1.473.10/0.90727 2.260.00 %0.79 %0.13 % 2.00
Dipna Pharmachem Ltd 18.3 Cr. 7.6024.1/7.4616.8 15.60.00 %8.49 %4.47 % 10.0
Decipher Labs Ltd 18.5 Cr. 18.325.8/14.4 21.60.00 %4.30 %7.46 % 10.0
Coral Laboratories Ltd 250 Cr. 700748/24515.7 4970.00 %12.6 %9.58 % 10.0
Concord Drugs Ltd 38.4 Cr. 38.461.5/28.291.4 33.80.00 %4.54 %1.29 % 10.0
Industry Average21,595.07 Cr1,333.4760.31208.520.35%17.51%17.08%6.44

Orchid Pharma Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales10312092128161178131165160210183199221
Expenses10812395116147152119147146170161175185
Operating Profit-5-4-311142612181440222335
OPM %-5%-3%-3%9%9%14%10%11%9%19%12%12%16%
Other Income211368-1-036934288
Interest13121110748987644
Depreciation292020202027221887889
Profit before tax-45-25-3149-14-5-14-3759112030
Tax %0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Profit-45-25-3149-14-7-15-585992029
EPS in Rs-10.96-6.06-7.5712.10-3.40-1.61-3.68-1.321.8614.491.853.905.80

Last Updated: July 10, 2024, 8:21 pm

Orchid Pharma Ltd Quarterly Chart

Orchid Pharma Ltd Profit & Loss

Last Updated: July 10, 2024, 8:21 pm

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,7821,8741,9481,747873797683600484450560666751
Expenses1,4371,5171,8371,429703794659612515421505581653
Operating Profit345357110317171324-12-3129558499
OPM %19%19%6%18%20%0%4%-2%-6%7%10%13%13%
Other Income775292156-28-59202182415675253
Interest1171805235372943473107652333325
Depreciation134154252325145141133130118109875531
Profit before tax17275-573-389-296-544-39969-131-11724897
Tax %9%-29%2%49%6%9%12%0%0%0%0%0%
Net Profit15697-560-197-279-495-35369-131-117-24696
EPS in Rs22.1713.84-79.21-23.06-31.37-55.69-39.657.80-32.11-28.55-0.4811.3522.10
Dividend Payout %14%22%0%0%0%0%0%0%0%0%0%0%

Orchid Pharma Ltd Profit & Loss Yearly Chart

Orchid Pharma Ltd Growth

Compounded Sales Growth
10 Years:-8%
5 Years:6%
3 Years:22%
TTM:23%
Compounded Profit Growth
10 Years:8%
5 Years:22%
3 Years:41%
TTM:1358%
Stock Price CAGR
10 Years:34%
5 Years:202%
3 Years:40%
1 Year:137%
Return on Equity
10 Years:%
5 Years:-5%
3 Years:4%
Last Year:10%

Last Updated: July 25, 2024, 6:41 am

Orchid Pharma Ltd Balance Sheet

Last Updated: July 10, 2024, 8:21 pm

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital70707085898989894141414151
Reserves9991,062310244-40-556-881-7937256126076481,057
Borrowings2,0792,0053,2043,2113,2153,1063,2023,230566453268331147
Other Liabilities7628011,067521598616715551128132195205237
Total Liabilities3,9103,9384,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,492
Fixed Assets1,7422,0742,5841,7951,6371,4971,3861,256858670584573564
CWIP332352360282280288272278267104663
Investments11111110015454447
Other Assets1,8351,5111,7061,9841,9441,4701,4671,542576544472561818
Total Assets3,9103,9384,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,492

Orchid Pharma Ltd Reserves and Borrowings Chart

Orchid Pharma Ltd Cash Flow

MonthMar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 737168-36921240191281249218126
Cash from Investing Activity -293-9861,334-1-176-284516767113-31-312
Cash from Financing Activity -480664-597-286-46533-0-250-165-21731167
Net Cash Flow-36-153367-76-2401557-2-74-1118-19

Orchid Pharma Ltd Financial Efficiency Indicators

MonthMar 2011Mar 2012Sep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days10522345413075647351110111118
Inventory Days259279187118220196202214254244201217
Days Payable141186220146341402374381182176195173
Cash Conversion Cycle224114-0269-130-108-94123179117163
Working Capital Days-3634-1138697-226-505-735166305136154
ROCE %10%8%-3%1%1%-4%-4%-5%-6%-5%-2%5%

Orchid Pharma Ltd Financial Efficiency Indicators Chart

Orchid Pharma Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters90.00%90.00%90.00%90.00%89.96%89.96%89.96%89.96%72.40%72.40%69.84%69.84%
FIIs1.82%1.79%1.78%1.61%1.48%1.37%0.86%0.81%8.58%8.08%4.14%1.96%
DIIs3.67%3.35%3.35%2.97%2.97%2.98%3.94%2.62%13.48%12.46%14.51%17.73%
Government0.00%0.04%0.04%0.04%0.04%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public4.51%4.83%4.84%5.39%5.55%5.69%5.22%6.60%5.54%7.05%11.52%10.47%
No. of Shareholders33,37934,79833,53333,69833,67932,71730,89429,52329,13229,19736,93136,720

Orchid Pharma Ltd Shareholding Pattern Chart

No. of Orchid Pharma Ltd Shareholders

Orchid Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund1,534,9190.7887.28668,4322024-07-22129.63%
Quant Multi Asset Fund1,262,5966.2371.8668,4322024-07-2288.89%
Nippon India Pharma Fund1,000,0000.9256.87668,4322024-07-2249.6%
Quant Value Fund668,4324.2938.01668,4322024-07-220%
UTI Small Cap Fund445,0000.7325.3668,4322024-07-22-33.43%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund269,6670.4715.33668,4322024-07-22-59.66%
Tata Multi Asset Opportunities Fund175,2600.489.97668,4322024-07-22-73.78%
Tata India Pharma & HealthCare Fund175,0001.329.95668,4322024-07-22-73.82%
UTI Healthcare Fund100,0000.675.69668,4322024-07-22-85.04%

Orchid Pharma Ltd ROCE Trend

Orchid Pharma Ltd EPS Trend

Orchid Pharma Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)19.0611.35-0.48-28.55-14.75
Diluted EPS (Rs.)19.0611.35-0.48-28.55-14.75
Cash EPS (Rs.)25.3025.3021.71-1.87-1.26
Book Value[Excl.RevalReserv]/Share (Rs.)230.58168.72158.61159.96250.97
Book Value[Incl.RevalReserv]/Share (Rs.)230.58168.72158.61159.96250.97
Revenue From Operations / Share (Rs.)161.55163.14137.09110.26124.47
PBDIT / Share (Rs.)27.9125.2515.2215.93-0.24
PBIT / Share (Rs.)21.3511.82-6.10-10.76-31.09
PBT / Share (Rs.)18.1313.54-13.94-23.34-32.11
Net Profit / Share (Rs.)18.7411.880.38-28.55-32.11
NP After MI And SOA / Share (Rs.)18.1711.35-0.47-28.55-32.11
PBDIT Margin (%)17.2715.4711.1014.44-0.19
PBIT Margin (%)13.217.24-4.44-9.75-24.98
PBT Margin (%)11.228.29-10.16-21.16-25.79
Net Profit Margin (%)11.607.270.28-25.89-25.79
NP After MI And SOA Margin (%)11.246.95-0.34-25.89-25.79
Return on Networth / Equity (%)7.886.72-0.30-17.84-12.79
Return on Capital Employeed (%)8.375.65-2.86-4.00-8.23
Return On Assets (%)5.933.78-0.17-9.41-7.61
Long Term Debt / Equity (X)0.100.210.320.650.48
Total Debt / Equity (X)0.110.480.410.650.48
Asset Turnover Ratio (%)0.580.570.470.300.21
Current Ratio (X)3.041.351.873.873.25
Quick Ratio (X)2.030.731.152.792.39
Inventory Turnover Ratio (X)2.142.022.091.601.44
Interest Coverage Ratio (X)8.653.201.941.27-0.23
Interest Coverage Ratio (Post Tax) (X)6.811.50-0.77-0.85-30.52
Enterprise Value (Cr.)5169.071869.701420.3010472.28346.98
EV / Net Operating Revenue (X)6.312.812.5423.270.68
EV / EBITDA (X)36.5218.1422.86161.10-350.31
MarketCap / Net Operating Revenue (X)6.472.362.0722.360.04
Price / BV (X)4.532.281.7915.410.02
Price / Net Operating Revenue (X)6.472.362.0722.360.04
EarningsYield0.010.020.00-0.01-6.12

Orchid Pharma Ltd Profitability Ratios (%)

Orchid Pharma Ltd Liquidity Ratios

Orchid Pharma Ltd Liquidity Ratios (%)

Orchid Pharma Ltd Interest Coverage Ratios (%)

Orchid Pharma Ltd Valuation Ratios

Fair Value

Fair Value: 1,762.36

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 28.64% compared to the current price 1370

Intrinsic Value: 3,930.96

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 186.93% compared to the current price 1370

Last 5 Year EPS CAGR: 123.05%

*Investments are subject to market risks

Strength and Weakness of Orchid Pharma Ltd

StrengthWeakness
  1. The stock has a low average Working Capital Days of -53.08, which is a positive sign.
  1. The stock has a low average ROCE of -0.33%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 51.92, which may not be favorable.
  3. The company has higher borrowings (1,910.50) compared to reserves (254.75), which may suggest financial risk.
  4. The company has not shown consistent growth in sales (451.38) and profit (-152.77).

Should I Buy Orchid Pharma Ltd Now?

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
    1. Net Profit Margin: 11.60%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 8.37% (Industry Average ROCE: 17.51%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ✓ ROE%: 7.88% (Industry Average ROE: 17.08%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 6.81
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.03
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✗ Stock P/E: 75.4 (Industry average Stock P/E: 60.31)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.11
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

FAQ

What is the latest fair value of Orchid Pharma Ltd?

The latest fair value of Orchid Pharma Ltd is ₹1762.36.

What is the Market Cap of Orchid Pharma Ltd?

The Market Cap of Orchid Pharma Ltd is 6,954 Cr..

What is the current Stock Price of Orchid Pharma Ltd as on 25 July 2024?

The current stock price of Orchid Pharma Ltd as on 25 July 2024 is 1,370.

What is the High / Low of Orchid Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Orchid Pharma Ltd stocks is 1,425/432.

What is the Stock P/E of Orchid Pharma Ltd?

The Stock P/E of Orchid Pharma Ltd is 75.4.

What is the Book Value of Orchid Pharma Ltd?

The Book Value of Orchid Pharma Ltd is 231.

What is the Dividend Yield of Orchid Pharma Ltd?

The Dividend Yield of Orchid Pharma Ltd is 0.00 %.

What is the ROCE of Orchid Pharma Ltd?

The ROCE of Orchid Pharma Ltd is 9.32 %.

What is the ROE of Orchid Pharma Ltd?

The ROE of Orchid Pharma Ltd is 9.92 %.

What is the Face Value of Orchid Pharma Ltd?

The Face Value of Orchid Pharma Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Orchid Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE